# Northwest Biotherapeutics Inc: overview NWBO · OTC · CIK 1072379 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nwbo.md) · [Financials](/companies/nwbo/financials.md) · [Filings](/companies/nwbo/filings.md) · [Insiders](/companies/nwbo/insiders.md) Latest reported revenue: [$807.0k](/filings/0001104659-26-097188.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-097188). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.4](/filings/0001104659-25-112676.md) | [0.2 d](/filings/0001104659-26-043806.md) | [0.4](/filings/0001104659-26-062661.md) | [0.1](/filings/0001104659-26-097188.md) | [0.2](/filings/0001104659-25-112676.md) | [0.7 d](/filings/0001104659-26-043806.md) | [0.5](/filings/0001104659-26-062661.md) | [0.8](/filings/0001104659-26-097188.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(4145.9%)](/filings/0001104659-25-112676.md) | [(8008.2%) d](/filings/0001104659-26-043806.md) | [(4616.3%)](/filings/0001104659-26-062661.md) | [(11281.7%)](/filings/0001104659-26-097188.md) | [(7160.0%)](/filings/0001104659-25-112676.md) | [(2009.5%) d](/filings/0001104659-26-043806.md) | [(2206.5%)](/filings/0001104659-26-062661.md) | [(1438.0%)](/filings/0001104659-26-097188.md) | | Net margin | % | [(5426.9%)](/filings/0001104659-25-112676.md) | [(12217.7%) d](/filings/0001104659-26-043806.md) | [(5158.1%)](/filings/0001104659-26-062661.md) | [(11738.9%)](/filings/0001104659-26-097188.md) | [(13414.5%)](/filings/0001104659-25-112676.md) | [206.5% d](/filings/0001104659-26-043806.md) | [(621.3%)](/filings/0001104659-26-062661.md) | [(1142.6%)](/filings/0001104659-26-097188.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [(0.01)](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) | [(0.02)](/filings/0001104659-25-112676.md) | not reported | [0.00](/filings/0001104659-26-062661.md) | [(0.01)](/filings/0001104659-26-097188.md) | | Free cash flow | $m | [(8.4) d](/filings/0001104659-25-112676.md) | [(20.3) d](/filings/0001104659-26-043806.md) | [(9.5)](/filings/0001104659-26-062661.md) | [(7.0) d](/filings/0001104659-26-097188.md) | [(14.1) d](/filings/0001104659-25-112676.md) | [(15.7) d](/filings/0001104659-26-043806.md) | [(12.6)](/filings/0001104659-26-062661.md) | [(7.4) d](/filings/0001104659-26-097188.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.0](/filings/0001410578-24-000133.md) | [1.7](/filings/0001410578-24-000133.md) | [1.9](/filings/0001410578-25-000598.md) | [1.4](/filings/0001104659-26-043806.md) | [1.4](/filings/0001104659-26-043806.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(5244.0%)](/filings/0001410578-24-000133.md) | [(3991.7%)](/filings/0001410578-24-000133.md) | [(2873.1%)](/filings/0001410578-25-000598.md) | [(4812.4%)](/filings/0001104659-26-043806.md) | [(4347.9%)](/filings/0001104659-26-043806.md) | | Net margin | % | [17823.5%](/filings/0001410578-24-000133.md) | [(6240.8%)](/filings/0001410578-24-000133.md) | [(3240.1%)](/filings/0001410578-25-000598.md) | [(6062.1%)](/filings/0001104659-26-043806.md) | [(4365.9%)](/filings/0001104659-26-043806.md) | | Diluted EPS | $ per share | [(0.06)](/filings/0001410578-24-000133.md) | [(0.10)](/filings/0001410578-24-000133.md) | [(0.06)](/filings/0001410578-25-000598.md) | [(0.07)](/filings/0001104659-26-043806.md) | [(0.04)](/filings/0001104659-26-043806.md) | | Free cash flow | $m | not reported | not reported | not reported | [(58.0)](/filings/0001104659-26-043806.md) | [(46.3)](/filings/0001104659-26-043806.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nwbo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [COMPASS FINANCIAL MANAGEMENT LLC](/funds/2148724.md) | 2026-06-30 | $227.1k | 1,215,500 | | Not compared | | [KELLEHER FINANCIAL ADVISORS](/funds/1507971.md) | 2026-06-30 | $149.4k | 800,000 | | Added +600,000 | | [VSM Wealth Advisory, LLC](/funds/2050660.md) | 2026-06-30 | $15.1k | 80,574 | | Unchanged | | [Ethos Financial Group, LLC](/funds/1954242.md) | 2026-06-30 | $6.3k | 39,070 | | Unchanged | | [Williams Jones Wealth Management, LLC.](/funds/1788587.md) | 2026-06-30 | $4.7k | 25,000 | | Unchanged | | [McIlrath & Eck, LLC](/funds/1701714.md) | 2026-03-31 | $124 | 600 | | Not compared | | [Opus Capital Group, LLC](/funds/1330325.md) | 2026-06-30 | $11 | 60,150 | | Unchanged | | [HANTZ FINANCIAL SERVICES, INC.](/funds/1071061.md) | 2026-06-30 | $0 | 250 | | Unchanged | | [Coston, McIsaac & Partners](/funds/1945037.md) | 2026-06-30 | $0 | 1,000 | | Unchanged | ## Recent filings [All 601 filings](/companies/nwbo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:10 ET | [8-K](/filings/0001104659-26-120669.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-26-120669 | | 2026-08-14 | 16:17 ET | [10-Q](/filings/0001104659-26-097188.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097188 | | 2026-07-31 | 17:17 ET | [8-K](/filings/0001104659-26-089293.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001104659-26-089293 | | 2026-07-20 | 19:48 ET | [8-K](/filings/0001104659-26-084743.md) | 7.01 Regulation FD disclosure | 0001104659-26-084743 | | 2026-05-15 | 16:34 ET | [10-Q](/filings/0001104659-26-062661.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062661 | | 2026-04-15 | 16:16 ET | [10-K](/filings/0001104659-26-043806.md) | Annual report, period 2025-12-31 | 0001104659-26-043806 | | 2026-04-07 | 12:30 ET | [8-K](/filings/0001104659-26-040260.md) | 2.01 Completion of an acquisition or disposition | 0001104659-26-040260 | | 2026-01-15 | 17:06 ET | [8-K](/filings/0001104659-26-004146.md) | 8.01 Other events | 0001104659-26-004146 | | 2026-01-02 | 17:14 ET | [8-K](/filings/0001104659-26-000243.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-000243 | | 2025-11-28 | 16:43 ET | [DEF 14A](/filings/0001104659-25-116966.md) | Proxy statement, period 2025-12-29 | 0001104659-25-116966 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-043806.md), filed Apr 15, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e1003f04-067e-4777-b614-697617dd48a3) ## About the filer - CIK: 1072379 - Tickers: NWBO - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:18 ET. No prices; not investment advice.